secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001213900-25-062800
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals regains Nasdaq equity compliance after $3.6M offering
---------------------------------------------------------------------------

- Received Nasdaq deficiency notice on May 23, 2025 for stockholders' equity of $2,126,662, below $2.5M minimum.
- Completed June 18, 2025 offering raising ~$3.6M gross via shares and warrants at $0.3251 per unit.
- Company believes it has now regained compliance with Nasdaq stockholders' equity requirement.
- Nasdaq will continue to monitor compliance; further non-compliance could lead to delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025062800/0001213900-25-062800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025062800/ea0248566-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-062800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer